Nerve Graft Surgery for Spinal Cord Injury
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two surgical approaches for treating spinal cord injuries. One group will undergo spinal decompression surgery alone, while the other will receive the same surgery plus a nerve graft. The nerve graft involves adding a piece of nerve from the leg to aid spine repair. The trial aims to determine if the nerve graft enhances the safety and effectiveness of the surgery. Individuals with a recent neck or upper back spinal cord injury who can undergo surgery within 48 hours may be suitable candidates for this trial. As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could improve surgical outcomes for future patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that a surgical procedure called dorsal myelotomy and expansive duraplasty (DMED), with or without autologous nerve graft implantation (ANGI), is under careful study for safety. In earlier studies, this surgery showed promise in treating spinal cord injuries. Most patients tolerated the procedure well, but all surgeries carry risks. Some patients might experience discomfort or complications, which are usually monitored closely.
For the nerve graft component, studies have shown that using a person's own nerve tissue is generally safe. This method avoids the need for immune-suppressing drugs, which are often required when using donor tissue. This type of transplant has shown positive results in aiding nerve recovery.
While researchers continue to study the treatment, these findings offer a hopeful outlook for safety. Prospective trial participants should discuss any concerns with their doctor.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the nerve graft surgery for spinal cord injury because it introduces a new approach by combining dorsal myelotomy and expansive duraplasty (DMED) with supplemental autologous nerve graft implantation (ANGI). Unlike traditional spinal decompression techniques, which primarily aim to relieve pressure on the spinal cord, this innovative method actively seeks to repair nerve damage by implanting the patient's own nerve tissue. This approach has the potential to enhance nerve regeneration and improve functional recovery, offering hope for more effective treatment outcomes in spinal cord injuries.
What evidence suggests that this trial's treatments could be effective for spinal cord injury?
Research has shown that dorsal myelotomy and expansive duraplasty (DMED), a procedure participants in this trial may receive, can enhance recovery after spinal cord injuries. Studies have found that early pressure relief on the spinal cord aids recovery. Myelotomy procedures have succeeded in 80% of animal studies and have shown positive results in human studies, improving movement and sensation.
The trial also explores combining DMED with autologous nerve graft implantation (ANGI). This approach uses a person's own nerve tissue to facilitate nerve growth across injury sites. It has successfully bridged gaps in the spinal cord and supported nerve regrowth. Overall, these treatments show promise in aiding recovery from spinal cord injuries.16789Who Is on the Research Team?
Francis H Farhadi, MD, PhD
Principal Investigator
University of Kentucky Neurosurgery
Are You a Good Fit for This Trial?
This trial is for adults aged 18-80 with acute traumatic spinal cord injury (SCI) at certain levels of the spine, who can consent and have surgery within 48 hours post-injury. Excluded are those with mild SCI, other serious conditions or mental impairments, substance abuse issues, pregnancy, involvement in another SCI study or if anterior-only spinal surgery is suitable.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo dorsal myelotomy and expansive duraplasty (DMED) with or without autologous nerve graft implantation (ANGI)
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nerve Graft Implantation
- Spinal Decompression
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Kentucky
Lead Sponsor
H. Francis Farhadi
Lead Sponsor
Francis Farhadi
Lead Sponsor
Spinal Cord and Brain Injury Research Center (SCOBIRC)
Collaborator